BELLUS Health Competitors

BELLUS Health (TSE:BLU) and Trillium Therapeutics Inc. (TRIL.TO) (TSE:TRIL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Earnings & Valuation

This table compares BELLUS Health and Trillium Therapeutics Inc. (TRIL.TO)'s revenue, earnings per share (EPS) and valuation.

BELLUS Health has higher earnings, but lower revenue than Trillium Therapeutics Inc. (TRIL.TO). BELLUS Health is trading at a lower price-to-earnings ratio than Trillium Therapeutics Inc. (TRIL.TO), indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for BELLUS Health and Trillium Therapeutics Inc. (TRIL.TO), as reported by MarketBeat.

Trillium Therapeutics Inc. (TRIL.TO) has a consensus target price of C$25.00, indicating a potential upside of 68.80%. Given Trillium Therapeutics Inc. (TRIL.TO)'s higher possible upside, analysts plainly believe Trillium Therapeutics Inc. (TRIL.TO) is more favorable than BELLUS Health.

Profitability

This table compares BELLUS Health and Trillium Therapeutics Inc. (TRIL.TO)'s net margins, return on equity and return on assets.

Summary

BELLUS Health beats Trillium Therapeutics Inc. (TRIL.TO) on 4 of the 7 factors compared between the two stocks.

Concordia International (TSE:CXR) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Profitability

This table compares Concordia International and BELLUS Health's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Concordia International and BELLUS Health's gross revenue, earnings per share (EPS) and valuation.

Concordia International has higher revenue and earnings than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than Concordia International, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Concordia International and BELLUS Health, as provided by MarketBeat.com.

Summary

Concordia International beats BELLUS Health on 4 of the 5 factors compared between the two stocks.

BELLUS Health (TSE:BLU) and Burcon NutraScience Co. (BU.TO) (TSE:BU) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Profitability

This table compares BELLUS Health and Burcon NutraScience Co. (BU.TO)'s net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations for BELLUS Health and Burcon NutraScience Co. (BU.TO), as provided by MarketBeat.com.

Burcon NutraScience Co. (BU.TO) has a consensus price target of C$5.00, suggesting a potential upside of 6.61%. Given Burcon NutraScience Co. (BU.TO)'s stronger consensus rating and higher possible upside, analysts clearly believe Burcon NutraScience Co. (BU.TO) is more favorable than BELLUS Health.

Valuation & Earnings

This table compares BELLUS Health and Burcon NutraScience Co. (BU.TO)'s revenue, earnings per share and valuation.

Burcon NutraScience Co. (BU.TO) has lower revenue, but higher earnings than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than Burcon NutraScience Co. (BU.TO), indicating that it is currently the more affordable of the two stocks.

Summary

Burcon NutraScience Co. (BU.TO) beats BELLUS Health on 6 of the 8 factors compared between the two stocks.

Aptose Biosciences (TSE:APS) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Aptose Biosciences and BELLUS Health, as reported by MarketBeat.

Aptose Biosciences presently has a consensus target price of C$12.00, suggesting a potential upside of 134.83%. Given Aptose Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Aptose Biosciences is more favorable than BELLUS Health.

Profitability

This table compares Aptose Biosciences and BELLUS Health's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Aptose Biosciences and BELLUS Health's gross revenue, earnings per share and valuation.

Aptose Biosciences has higher earnings, but lower revenue than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Aptose Biosciences beats BELLUS Health on 3 of the 5 factors compared between the two stocks.

BELLUS Health (TSE:BLU) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for BELLUS Health and Theratechnologies, as reported by MarketBeat.com.

Theratechnologies has a consensus target price of C$3.75, suggesting a potential downside of 15.16%. Given Theratechnologies' higher probable upside, analysts plainly believe Theratechnologies is more favorable than BELLUS Health.

Valuation & Earnings

This table compares BELLUS Health and Theratechnologies' top-line revenue, earnings per share (EPS) and valuation.

Theratechnologies has higher revenue and earnings than BELLUS Health. Theratechnologies is trading at a lower price-to-earnings ratio than BELLUS Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BELLUS Health and Theratechnologies' net margins, return on equity and return on assets.

Neptune Wellness Solutions (TSE:NEPT) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Profitability

This table compares Neptune Wellness Solutions and BELLUS Health's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Neptune Wellness Solutions and BELLUS Health, as provided by MarketBeat.com.

Neptune Wellness Solutions presently has a consensus price target of C$4.63, indicating a potential upside of 131.25%. Given Neptune Wellness Solutions' stronger consensus rating and higher possible upside, analysts clearly believe Neptune Wellness Solutions is more favorable than BELLUS Health.

Valuation and Earnings

This table compares Neptune Wellness Solutions and BELLUS Health's revenue, earnings per share and valuation.

BELLUS Health has lower revenue, but higher earnings than Neptune Wellness Solutions. BELLUS Health is trading at a lower price-to-earnings ratio than Neptune Wellness Solutions, indicating that it is currently the more affordable of the two stocks.